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Summory
This thesis focuses on some diagnostic and clinical aspects ofgrowth hormone (GH) and
adrenocorticotropic hormone (ACTH) deficiency in adults.
It is now widely recognised that GH has an important role in the health of adults as well as
in the development of children. The availability of biosynthetic GH made it possible to
investigate the effects of GH in adults with GH deficiency more extensively.
ln chapter I (general introduction) several features ofGH and insulinlike growth factor-I
(IGF-[) are discussed. GH is synthesised in the anterior lobe of the pituitary and its secretion
is dependent ofvarious physiological factors as well as hormones from the hlpothalamus, like
growth hormone releasing hormone (GHRH) and somatostatin. GH has a biphasic effect on
glucose, free fatty acids (FFA) and amino acid levels in plasma: a lowering effect like insulin,
followed by increased mobilisation of FFA (lipolysis) and diminished glucose utilisation.
Many effects of GH are mediated by IGF-I, which is mainly s1'nthesised in the liver. IGF-I
has a potent mitogenic action, especially on immature differentiating cells. IGF-I is bound to
specific carrier proteins (lGF binding proteins, IGFBP), which are considered to modulate
IGF action in vivo.
GH deficiency in adults is recognised as a distinct clinical entity. The most prominent features
of GH deficiency in adults are altered bodycomposition ('more fat, less muscle'), impaired
quality oflife and reduced physical strength. There is also an increase in cardiovascular isk
factors, such as an unÍavourable lipid profile and central obesity.
The biochemical diagnosis of GH deficiency in adults can be assessed by various (mostly
non-physiologic provocative) tests. The insulin tolerance test (ITT) is nowadays still
considered to be the golden standard. This test and others are briefly discussed, including the
promising GH Releasing Peptide 6-GHRH test.
The beneficial effect of GH in children with GH deficiency is known since the late 1950s.
Due to the limited supply, it was not possible to treat adults until biosynthetic human GH
could be manufactured around 1985. GH substitution in GH deficient adults has a positive
effect on body composition due to the anabolic and lipolytic action, leading to reduction of fat
mass and an increase in total body wateÍ content (fat free mass). Exercise capacity increases
too after GH replacement herapy. Adults with GH deficiency have both a reduced rate of
bone formation and reduced mineral mass. GH replacement herapy initially reduces bone
mineral mass slightly, due to remodelling, but aÍter approximately one year bone mineral
mass increases to levels above baseline.
Adults with GH deficiency suffer from increased morbidity and mortality, in part as a result
of cardiovascular events. These patients show adverse lipid profiles, which are supposed to
contribute to morbidity. GH replacement herapy has been shown to have favourable efÍècts
on total cholesterol and LDL cholesterol, but the effect on HDL cholesterol seems to be
variable.
Among the stimulation tests to evaluate GH secretion capacity, the GH-releasing hormone
stimulation (GHRH) test has the advantage above the insulin tolerance test (ITT) of being less
cumbersome. However, these two tests have never been compared extensively. Furthermore,
pituitary GH release is directly stimulated by GHRH, whereas GH stimulation after
hypoglycaemia is considered to be the result of inhibition of the hypothalamic somatostatin
secretion, making the equality between these tests not self-evident. Therefore, in chapter 2
the GH responses to the insulin tolerance test (ITT) and growth hormone-releasing hormone
(GHRH) test are evaluated in 34 adults with untreated non-functioning pituitary
macroadenomas. Comparisons between these two tests are made after stratifying the patients
for serum prolactin level as an indication of hypothalamic-pituitary dysfunction and for the
. \  t t tnt tru r t
numbcr of dher pituitary hormone deÍrciencics. ln the whole group the median peak GH lcvel
to GHRH was higher than to ITT, but this dif ïerence was only observed in the group with
hyperprolact inaemia. Anrong the patients with hyperprolaci inaernia, an insufl icient GH peak
aÍier ITT occurred mure often than aÍier GHRH stirnulation. Peak GH to ITT was illso lower
in patients with other pituitary hormone deÍlciencies than in patients without other
deÍicicncies. ln contrast. GHRH-stimulatcd GH was not related to the numbcr of other
pituitary hormone def iciencies. These results show that the ITT and GHRH-tesl are not
equivalent in assessing the somatotroph axis in patients with non-Íunctioning pituitary
macroadenoma nd hypefprolactinaernia. It is statcd that thcse test results differ dLre to a
diÍ1èrent mechanism of act ion of these st imuli .  Hyperprolact inaemia r.nay be ass<rciated with a
Iower sornatostat in tule. elevating both basal and GHRH stirnulated GH, with no inf lucncc on
peak GH to ITT.
Acromegalic patients harboul an increased r isk ofdeveloping colorectal canccr. I t  is
unknown whether prolonged GH leplacernent therapy in GH dcÍlcient adr-r l ts is a r isk lactor
l i rr  acquir in-v such a rnal ignancy. In chapter 3 the resuhs ol 'a randomisecl.  placcbo control led
sludy in l6 GH deÍicicnt adults arc presented. in which the colonic epithcl ial  prol i fèrat ion
rate, as a bionarkcr ofthc risk ofdevcloping colorcctal canccf. was mcasurecl bcfbrc and after
6 antl  l2 nronths treatmcnt. This prol i ferat ion rate was sinri lar beÍbre and al iel  GH
rcplacenrent thefapy Íbr 6 months (n=81 AÍier l2 rnonths treatrrent, no changes cornparcd to
baselinc wcre observed either (n=9). Separate valuation ofthc plol i Íèrat ion rate at the blsal.
nrid ancl lunrinal port ions o1'the cnlonic crypts also Í ir i led to show any eÍ lèct of GH treatnent.
I t w a s c o n c l u d e d t h a t 6 t o  l 2 m o n t h s o f  G H r e p l a c e m e n t t h c r a p y w i t h Í G F - l l e v e l s i n t h e h i g h
physiolo-t ical range does not adversely affect colonic epithel ial cel l  plol i fèrat ion as a
biomarker lbr the r isk o1'de velopin-e colorectal cancer.
Both GH del icicncy and acromcgaly are associated with an increased cardiovascular r isk,
which nray in palt  be attr ibutable to l ipid and l ipoprotcin abnolmali t ics. Lit t lc is known about
High Dcnsity Lipoplotein (HDL) metabolism in both condit iorrs. Chapter 4 deals with the
question whether GH dcÍiciency and acromegaly i l re associatecl with abnormali t ies in
HDL cholcsteryl estcr and l iec cholcsterol concentrat ions, and whether possible changes in
plasma lecithin:cholcsterol acyltranslèrase (LCAT), cholesteryl estel transÍ 'cr protcin (CETP)
and phospholipid transl 'cr protcin (PLTP), làctors involved in HDL nretabolism. would at ' fect
plasrna cholestelol estel i Í icat ion and cholesteryl ester transfèr in thesc condit ions. Twelve
untrcatcd GH dcf icicnt men, l2 acrome-{al ic patients and 24 healthy rnalcs werc investigated.
Conrparcd to hcalthy subjects. HDL cholcstcrol and HDL cholesteryl cstcr were lowel in both
CH del ' ic ient and aclonregalic patients. Plaslna LCAT, CETP and PLTP activi ty levels were
Iowcr in acronregalic patients and CETP activi ty was Iowel in the GH de Í lcient putients
crlmpared to healthy subjects. Both plasma cholesterol cstel i Í lcat ion (EST) and cholesteryl
csler translèr '(CET) wcre decreased in acromcgalic as well  as in GH dcl ' ic ient patients.
Indeperrdent e-gi l t ive relat ionships were lbund between plasma ICF-l and plasma LCAT.
CIETP and PLTP activi ty levels. Thus. GH deÍ ' icient and aclonregalic patients show
abnornral i t ies in HDL rnetabolism, consistcnt with irnpaired I,CAT action. Thc utrncrlnitunt
cleclcasc in plasnra EST and CET suggests that rcverse cholesterol t l rnsport may be
cl iminishecl. contr ibuting to increased cardiovascular r isk.
In chapter 5 the inf luence oÍ-GH replacement thcrapy on LCAT. CETP and PLTP was
studiecl in 2:1 GH del lcient adults. In thc l i rst (r months, these patients wcre randomised to
placebo (n=8). low dose GH ( I  U dai ly. n=8) and high dose GH (2 U dai ly. n=8), fbl lowcd by
a 6 nronths open extension study with high dose GH. Alter 6 r lonths of GH replaccmcnl. thc
lcvels of plasrna VLDL+LDL cholesterol and apolipoplotein B dccrci-rscd. whcreas
HDL cholcsterol and HDL cholesteryl estef incleasecl. Plasrna LCAT and CETP activi ty
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The data support the notion that GH replacement herapy is beneficial to the lipoprotein
profile in GH deficient adults. Prolonged replacement herapy decreases plasma LCAT and
CETP activity levels, contributing to a decrease in plasma cholesterol esterification and
cholesteryl ester transÍèr.
The hypothalamus, pituitary and adrenal form a neuroendocrine axis, which regulates
cortisol production and release in the adrenal cortex. Methods of evaluating the HPA-axis in
(suspected) cortisol deficiency include measurement ofbasal serum cortisol and plasma
ACTH concentrations, the ACTH stimulation test and dynamic tests to assess ACTH reserve
(e.g. ITT). Patients can show variable test Íesults due to variation in site ofthe primary lesion
(adrenal or central), but also due to the duration and extent ofthe disease. The latter issue
explains a normal cortisol response in the ACTH test in recent-onset ACTH deficiency or
partial primary adrenal insufficiency.
In assessing the integrity of the hypothalamic-pituitary-adrenal xis (HPA-axis), the ITT is
widely used and considered as the golden standard by many investigators. However, this test
has the disadvantage ofbeing cumbersome and dangerous for certain patients as well. A
screening test would be beneficial to limit the amount of patients that needs the ITT.
Therefbre, in chapter 6 the perÍbrmance of screening tests (serum cortisol at 0800 h and
l6a) h,24-h urinary free cortisol) and the human-corticotrophin releasing hormone test is
demonstrated in 80 patients with hypothalamic-pituitary disorders and compared with the
results of the ITT. When comparing the screening tests, it was Íbund that the diagnostic yield
for the 08m h serum cortisol was significantly larger than fbr the l6tx)h serurn cortisol and
24-h urinary free cortisol. No difference was observed in the pre- and postoperative
evaluation of 08(x)h serum cortisol. The human-Corticotrophin Releasing Hormone test did
not perform better as cornpared with the 0800 h selum cortisol. [t was concludetl that the
0800 h serum cortisol measurement serves as the best screening test to evaluate the adrenal
function in hypothalamic-pituitary disorders with the ITT as the réference test.
As there are no data with respect to the effect of glucocorticoid replacement herapy on
HDL metabolism in hypopituitary subjects, the possible inÍluence ofconventional
glucocorticoid replacement herapy on plasma tipids, plasma LCAT, CETP and PLTP activity
levels, as well as on plasma cholesterol esterification (EST) and cholesteryl ester transfèr
(CET) was evaluated in 24 hypopituitary patients. These results are described in chapter 7.
Plasma total and VLDL+LDL cholesterol were lower in patients on glucocorticoid therapy,
but there were no difÍ'erences in HDL cholesterol and triglycerides. Plasma LCAT was 45%
lower and CETP 34Vo lower in patients on glucocorticoid therapy. These eÍïècts were
independent of gender and fat mass. Plasma EST and CET were also decreased in
glucocorticoid-receiving patients, and these changes are at least partly attributable to lower
LCAT and CETP activity levels. There was no difïèrence found in plasma PLTP activity
between patients with and without glucocorticoid treatment, suggesting a diÍïerent regulatory
effect on plasma CETP compared to PLTP. It is concluded that parameters ofreverse
cholesterol transport are impaired in patients receiving conventional glucocorticoid
replacement herapy. Such disturbances of HDL metabolism could be involved in increased
cardiovascular isk in glucocorticoid-treated hypopituitary patients, despite the lack of an
unÍàvourable plasma lipid profile.
The conversion ofcortisone to cortisol by I lB hydroxysteroid dehydrogenase type I
( I IBHSDT) may be diminished as a result of GH replacement herapy. As a consequence, this
efÍ'ect would lower the bioavailability of cortisone acetate in patients with adrenal
insufÍiciency, who are treated with cortisone acetate in stead ofhydrocortisone tablets.
Chapter 8 describes the results ofa randomised, placebo-controlled GH replacement study in
24 patients (17 subjects on cortisone acetate) during 6 months (0 to 2 U GH/day), fbllowed by
133
a 6 months open extension study (2 U GIVday). The influence of GH replacement herapy on
the setpoint ofthe cortisol to cortisone interconversion was evaluated. After 6 months placebo
no changes in urinary cortisol metabolites were observed. The urinmy (TIIF + alloTï{F)/TIIE
ratio was unaltered in cortisone acetate freated patients and in patients with intact adrenal
function after 6 months GH, whereas after 12 months GH the (TIIF + alloTIIF)/THE ratio
decreased only in cortisone acetate treated patients. Urinary TIIF and alloTTIF were higher in
cortisone acetate treated patients than in patients with intact adrenal function before GH and
remained so after 12 months GH. The slm of cortisol + cortisone metabolites did not change
after GH in either group. These reults support the possibility that GH replacement decreases
I lÊHSDr activity, which becomes manifest in patients receiving a conventional dose of
cortisone acntate. The I I FHSDz activity does not decrease. The observation that cortisone
acetate treaonent is disadvantageous in adrenal insufficiency, or that the bioavailability of
cortisone acetate tablets is impaired during GH replacement, is not supported by this sody.
